semaglutide compounding deadline The weight loss drug shortage is over — and some patients are 'panicking' How the FDA's Semaglutide Ruling

Those who took tirzepatide lost 15.7%, or 34.4 pounds, of body weight on average when compared to those on a placebo, who lost 3.3% of their weight, or 7 pounds, on average

But this convenience has also created a Wild West of providers, pricing models, and service levels

Lee: There is growing interest in how GLP-1 medications may influence the brains reward system, particularly dopamine signaling

Real-world data show that many patients discontinue much sooner than optimal, often before the full benefits can be realized

Cortisol, thyroid hormones, estrogen, progesterone, and testosterone all influence weight regulation

The Triple-Agonist Breakthrough Retatrutide (LY3437943), developed by Eli Lilly, is an investigational triple-agonist peptide that activates three metabolic receptors simultaneously: GLP-1, GIP, and the glucagon receptor